Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

BMS's ACE/NEP inhibitors in phase I

April 26, 1996

Yamanouchi selects YM-471 for clinical development

April 19, 1996

Corvert now available in U.S.

April 19, 1996

Posicor submitted for approval

April 19, 1996

New ETA antagonist from SmithKline Beecham: SB-225757

April 19, 1996

EMD-94246, promising endothelin antagonist for hypertension

April 19, 1996

Zanidip approved for marketing in U.K.

April 19, 1996

CP-191166, angiotensin II antagonist from Pfizer

April 19, 1996

YM-087 in phase I for CHF

April 12, 1996

New angiotensin II antagonists from Kotobuki

April 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...